Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 1, 2028

Study Completion Date

August 1, 2030

Conditions

Diffuse Large B-Cell Lymphoma (DLBCL)

Interventions

DRUG

Xinlikang capsules

Xinlikang capsules after meals, 5 capsules each time, 3 times a day for 12 weeks

DRUG

mimic capsules

mimic capsules, 5 capsules each time after meals, 3 times a day for 12 weeks.

All Listed Sponsors

lead

Sun Yat-sen University

OTHER

NCT07084662 - Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma | Biotech Hunter | Biotech Hunter